Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Cited by (1,019)

Items 801–900 of 1,019

1. Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
   Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba, Eriko Miyawaki, Junichi Shimizu, Tomohiro Ozaki, Daichi Fujimoto, Ryo Toyozawa, Atsushi Nakamura, Toshiyuki Kozuki et al. · 2020 · Journal for ImmunoTherapy of Cancer
2. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
   Andrea Botticelli, Alessio Cirillo, Simone Scagnoli, Bruna Cerbelli, Lidia Strigari, Alessio Cortellini, Laura Pizzuti, Patrizia Vici, Federica De Galitiis, Francesca Romana Di Pietro et al. · 2020 · Vaccines
3. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
   Shang-Jui Wang, Karishma Khullar, Sinae Kim, Nikhil Yegya‐Raman, Jyoti Dhar Malhotra, Roman Groisberg, Samuel H Crayton, Ann Willman Silk, John L. Nosher, Michael A Gentile et al. · 2020 · Journal for ImmunoTherapy of Cancer
4. Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
   Hidehito Horinouchi, Naoyuki Nogami, Hideo Saka, Makoto Nishio, Takaaki Tokito, Toshiaki Takahashi, Kazuo Kasahara, Yoshihiro Hattori, Eiki Ichihara, Noriaki Adachi et al. · 2021 · Cancer Science
5. Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
   Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco et al. · 2020 · Cancers
6. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
   Shen Lin, Shaohong Luo, Lixian Zhong, Shubin Lai, Dayong Zeng, Xin Rao, Pinfang Huang, Xiuhua Weng · 2020 · International Journal of Clinical Pharmacy
7. The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
   Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier‐Luigi Lollini, Andrea Ardizzoni, Francesco Gelsomino · 2020 · Cancers
8. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
   Chia-Sing Lu, Ching‐Wen Lin, Ya-Hsuan Chang, Hsuan‐Yu Chen, Wei-Chia Chung, Wei‐Yun Lai, Chao‐Chi Ho, Tong‐Hong Wang, Chi‐Yuan Chen, Chen-Lin Yeh et al. · 2020 · Journal for ImmunoTherapy of Cancer
9. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
   Elizabeth Dudnik, Mor Tal Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem et al. · 2021 · OncoImmunology
10. Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors
    Clara García-Carro, Mónica Bolufer, Roxana Bury, Zaira Castañeda, Eva Muñoz‐Couselo, Enriqueta Felip, D. Lorente, María Josep Carreras, Alejandra Gabaldón, Irene Agraz et al. · 2021 · Nephrology Dialysis Transplantation
11. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
    Xiangyu Zhang, Liang Zeng, Yizhi Li, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Xinru Mao, Renan Jin, Yu Zeng, Qinglin Li et al. · 2021 · Cancer Immunology Immunotherapy
12. Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
    Selina K. Wong, Caroline A. Nebhan, Douglas Buckner Johnson · 2021 · Frontiers in Immunology
13. Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
    Jordan W. Conway, Robert V. Rawson, Serigne Lo, Tasnia Ahmed, Ismael A. Vergara, Tuba Nur Gide, Grace Heloise Attrill, Matteo Salvatore Carlino, Robyn P.M. Saw, John F. Thompson et al. · 2022 · Journal for ImmunoTherapy of Cancer
14. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
    Foluso Olabisi Ademuyiwa, Feng Gao, Cherease Street, Ina Chen, DW Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, Elizabeth Claire Dees, Cesar Augusto Santa-Maria et al. · 2022 · npj Breast Cancer
15. Patient performance status and cancer immunotherapy efficacy: a meta-analysis
    Melissa Bersanelli, Matteo Brighenti, Sebastiano Buti, Sandro Barni, Fausto Petrelli · 2018 · Medical Oncology
16. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
    Mohammad Jafarnejad, Chang Gong, Edward Gabrielson, Imke Heleen Bartelink, Paolo Vicini, Bing Wang, Rajesh Narwal, Lorin K. Roskos, Aleksander S. Popel · 2019 · The AAPS Journal
17. Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
    Jingli Lü, Lulu Li, Yan Lan, Yan Liang, Haiyang Meng · 2019 · Cancer Medicine
18. Cytology for PD-L1 testing: A systematic review
    John R. Gosney, Anne-Marie Boothman, M. Ratcliffe, Keith M. Kerr · 2020 · Lung Cancer
19. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study
    Akihito Kawazoe, Kensei Yamaguchi, Hisateru Yasui, Yuji Negoro, Mizutomo Azuma, Kenji Amagai, Hiroki Hara, Hideo Baba, Masahiro Tsuda, Hisashi Hosaka et al. · 2020 · European Journal of Cancer
20. A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients
    Zhijie Wang, Jun Zhao, Zhiyong Ma, Jiuwei Cui, Yongqian Shu, Zhe Liu, Ying Cheng, Shiang Jiin Leaw, Yanjie Wu, Yan Ma et al. · 2020 · Lung Cancer
21. Advances in Small-Cell Lung Cancer (SCLC) Translational Research
    Benjamin Jacob Drapkin, Charles M. Rudin · 2020 · Cold Spring Harbor Perspectives in Medicine
22. The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke)
    Barca, Cristina, Foray, Claudia, Hermann, Sven, Herrlinger, Ulrich, Remory, Isabel, Laoui, Damya, Schäfers, Michael, Grauer, Oliver M., Zinnhardt, Bastian, Jacobs, Andreas H. · 2021 · Frontiers in Immunology
23. Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer
    Zhang, Chengxiang, Zhang, Xinfu, Zhao, Weiyu, Zeng, Chunxi, Li, Wenqing, Li, Bin, Luo, Xiao, Li, Junan, Jiang, Justin, Deng, Binbin et al. · 2019 · Nano Research
24. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer
    Emmett V. Schmidt · 2018 · Seminars in Immunopathology
25. Cancer immunotherapy: the art of targeting the tumor immune microenvironment
    Jessé Lopes da Silva, Alexssandra Lima Siqueira dos Santos, Natália Cristina Cardoso Nunes, Flora de Moraes Lino da Silva, Carlos Gil Ferreira, Andréia Cristina de Melo · 2019 · Cancer Chemotherapy and Pharmacology
26. Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
    Patrick J. Roberts, Vishnu Muthuraj Kumarasamy, Agnieszka Katarzyna Witkiewicz, Erik S. Knudsen · 2020 · Molecular Cancer Therapeutics
27. Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
    Rilan Bai, Lingyu Li, Xiao Chen, Naifei Chen, Wei Song, Jiuwei Cui · 2020 · Frontiers in Oncology
28. Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients
    Janice J.N. Li, Khizar Karim, Mike Sung, Lisa W. Le, Sally C. M. Lau, Adrian G. Sacher, Natasha B. Leighl · 2020 · Lung Cancer
29. Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications
    Wei Sun, Qing Zhang, Runkun Wang, Li Yang, Yue Sun, Lin Yang · 2021 · Frontiers in Oncology
30. Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer
    Kenji Morimoto, Tadaaki Yamada, Takashi Yokoi, Takashi Kijima, Yasuhiro Gotô, Akira Nakao, Makoto Hibino, Takayuki Takeda, Hiroyuki Yamaguchi, Chieko Takumi et al. · 2021 · Lung Cancer
31. Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota
    Zishuo Ian Hu, Verena M. Link, Djalma Souza Lima-Junior, Jeremie Delaleu, Nicolas Jean Bouladoux, Seong‐Ji Han, Nicholas Collins, Yasmine Belkaid · 2022 · Proceedings of the National Academy of Sciences
32. Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives
    Ugur T. Sener, Michael W. Ruff, Jian Li Campian · 2022 · International Journal of Molecular Sciences
33. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
    Solange Peters, Luis G Paz-Ares, Roy S. Herbst, Martin Reck · 2022 · Journal for ImmunoTherapy of Cancer
34. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study
    Chongwu Li, Junqi Wu, Long Jiang, Lei Zhang, Jia Huang, Yu Tian, Yue Zhao, Xiucheng Liu, Lang Xia, E Haoran et al. · 2022 · Cancer Immunology Immunotherapy
35. Immunobiology of cholangiocarcinoma
    Jennifer L. Tomlinson, Juan W. Valle, Sumera Irie Ilyas · 2023 · Journal of Hepatology
36. Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review
    Alejandro Olivares-Hernández, Elisabet González-Del Portillo, Álvaro Tamayo-Velasco, Luis Figuero-Pérez, Svetlana Zhilina-Zhilina, Emilio Fonseca‐Sánchez, José Pablo Miramontes‐González · 2023 · Annals of Translational Medicine
37. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
    Ishmael A. Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, Krishna Chaitanya Alluri, Narjust Florez, Shirish M. Gadgeel, Gregory A. Masters, Erin Lynn Schenk, Bryan James Schneider, Lecia Van Dam Sequist et al. · 2024 · Journal of Clinical Oncology
38. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer
    Yoko Tsukita, Takehiro Tozuka, Kohei Kushiro, Shinobu Hosokawa, Toshiyuki Sumi, Mao Uematsu, Osamu Honjo, Ou Yamaguchi, Tetsuhiko Asao, Jun Sugisaka et al. · 2024 · JAMA Oncology
39. Opportunities and challenges of targeting cGAS–STING in cancer
    Changzheng Lu, Wenyan Wang, Yang‐Xin Fu · 2026 · Nature reviews. Cancer
40. Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
    Vito Longo, Oronzo Brunetti, Amalia Azzariti, Domenico Galetta, Patrizia Nardulli, Francesco Leonetti, Nicola Silvestris · 2019 · Cancers
41. Imaging of Precision Therapy for Lung Cancer: Current State of the Art
    Hyesun Park, Lynette Marie Sholl, Hiroto Hatabu, Mark Magdi Awad, Mizuki Nishino · 2019 · Radiology
42. Evolution of treatment strategies for oligometastatic NSCLC patients – A systematic review of the literature
    Daniel Hendrik Schanne, Jana Schaule, Matthias Gückenberger, Nicolaus H. Andratschke · 2019 · Cancer Treatment Reviews
43. Implementing a multidisciplinary approach for older adults with Cancer: geriatric oncology in practice
    Carolyn Jean Presley, Jessica L. Krok‐Schoen, Sarah Allison Wall, Anne M. Noonan, Desirée Jones, Edmund Folefac, Nicole Olivia Williams, Janine A Overcash, Ashley Elizabeth Rosko · 2020 · BMC Geriatrics
44. Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
    Chaoyue Su, Hui Wang, Yunru Liu, Qiaoru Guo, Lingling Zhang, Jiajun Li, Wenmin Zhou, Yanyan Yan, Xinke Zhou, Jianye Zhang · 2020 · Frontiers in Oncology
45. Pembrolizumab for the treatment of cervical cancer
    Grégoire Marret, Édith Borcoman, Christophe Le Tourneau · 2019 · Expert Opinion on Biological Therapy
46. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors
    Anne Schett, Sacha I. Rothschild, Alessandra Curioni Fontecedro, Stephan Krähenbühl, Martin Früh, Sabine Schmid, Christoph Driessen, Markus Joerger · 2019 · Cancer Chemotherapy and Pharmacology
47. The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer
    Bao‐Dong Qin, Xiao‐Dong Jiao, Jun Liu, Ke Liu, Xi He, Ying Xing Wu, Yan Ling, Xiao-Peng Duan, Wenxing Qin, Zhan Wang et al. · 2020 · Critical Reviews in Oncology/Hematology
48. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
    Xue Bai, Dehua Wu, Si-Cong Ma, Jian Wang, Xin-Ran Tang, Shuai Kang, Qiang John Fu, Chuanhui Cao, He-San Luo, Yuhan Chen et al. · 2020 · Journal for ImmunoTherapy of Cancer
49. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
    Haiping Jiang, Yulong Zheng, Jiong Qian, Chenyu Mao, Xin Xu, Ning Li, Xiao Cheng, Huan Wang, Lisong Teng, Hui Zhou et al. · 2020 · BMC Cancer
50. Impact of PET/CT for Assessing Response to Immunotherapy—A Clinical Perspective
    David Lang, Gerald Wahl, Nikolaus Poier-Fabian, Sebastian Graf, David Kiesl, Bernd Lamprecht, Michael Gabriel · 2020 · Journal of Clinical Medicine
51. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer
    Ramón Palmero, Álvaro Taus, Santiago Viteri, Margarita Majem, Enric Carcereny, Javier Garde, Enriqueta Felip, Ernest Nadal, Andrea Malfettone, Miguel Sampayo-Cordero et al. · 2021 · JCO Precision Oncology
52. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
    Noura J. Choudhury, Adam Jacob Schoenfeld, Jessica R. Flynn, Christina J. Falcon, Hira A. Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena Alexandra Yu et al. · 2021 · Clinical Cancer Research
53. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice
    Petros D. Grivas, Neeraj Agarwal, Sumanta Kumar Pal, Arash Rezazadeh Kalebasty, Srikala S. Sridhar, Jodi Smith, Geeta Devgan, Cora Nanette Sternberg, Joaquim Bellmunt B · 2021 · Cancer Treatment Reviews
54. Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities
    Davood Bashash, Zahra Zandi, Bahareh Kashani, Atieh Pourbagheri‐Sigaroodi, Sina Salari, Seyed Hamidollah Ghaffari · 2021 · Journal of Cellular Physiology
55. Fracture Risk Evaluation of Bone Metastases: A Burning Issue
    Cyrille B. Confavreux, Hélène Follet, David Mitton, Jean‐Baptiste Pialat, Philippe Clézardin · 2021 · Cancers
56. Glioma and the gut–brain axis: opportunities and future perspectives
    Antonio Dono, Jack Nickles, Ana G. Rodriguez-Armendariz, Braden C. McFarland, Nadim J. Ajami, Leomar Y. Ballester, Jennifer Ann Wargo, Yoshua Esquenazi · 2022 · Neuro-Oncology Advances
57. Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
    Mahesh Koirala, Mario DiPaola · 2024 · Biomedicines
58. EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis
    Francesco Agustoni, Kenichi Suda, Hui Yu, Shengxiang Ren, Christopher J. Rivard, Kim E. Ellison, Charles Caldwell, Leslie M. Rozeboom, Kristine A. Brovsky, Fred R. Hirsch · 2018 · Cancer Treatment Reviews
59. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
    Jose M. Pacheco, D. Ross Camidge, Robert Charles Doebele, Erin Lynn Schenk · 2019 · Frontiers in Oncology
60. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
    Andrea Botticelli, Massimiliano Salati, Francesca Romana Di Pietro, Lidia Strigari, Bruna Cerbelli, Ilaria Grazia Zizzari, Raffaele Giusti, Marco Mazzotta, Federica Mazzuca, Michela Roberto et al. · 2019 · Journal of Translational Medicine
61. The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
    Birgit Guldhammer Skov, Sara Bird Rørvig, T. Jensen, Torsten Skov · 2019 · Modern Pathology
62. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
    Longjiang She, Huabin Hu, Mengting Liao, Xuefeng Xia, Yin Shi, Linli Yao, Dong Ding, Youwen Zhu, Shan Zeng, Liangfang Shen et al. · 2019 · Lung Cancer
63. Roles of microbiota in response to cancer immunotherapy
    Kentaro Inamura · 2020 · Seminars in Cancer Biology
64. First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation
    Joseph Nicholas Bodor, Vineela Kasireddy, Hossein Borghaei · 2018 · Journal of Oncology Practice
65. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC
    Yaru Tian, Xiaoyang Zhai, Weiwei Yan, Hui Zhu, Jinming Yu · 2020 · Cancer Medicine
66. Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors
    Na Liu, Aimin Jiang, Xiaoqiang Zheng, Xiao Fu, Haoran Zheng, Huan Gao, Jingjing Wang, Xuan Liang, Tao Tian, Zhiping Ruan et al. · 2021 · Journal of Cancer
67. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy
    Yu Chen Zhao, Yuejiao Cao, Yiqi Chen, Lei Wu, Hua Hang, Chenxia Jiang, Xiaorong Zhou · 2021 · Immunology
68. Disparities in Lung Cancer Treatment
    Sharon Harrison, Julia Judd, Sheray Nicole Chin, Camille C. Rose Ragin · 2022 · Current Oncology Reports
69. Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas
    Ana Belén Griso-Acevedo, Lucía Acero-Riaguas, Beatriz Castelo, José Luis Cebrián Carretero, Ana Sastre-Perona · 2022 · Cells
70. Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer
    Mark Stares, Tze-en Ding, Cory Stratton, Findlay Thomson, Mark A Baxter, Hannah P. Cagney, Kirsty Cumming, Amanda M. Swan, F. Ross, C. Barrie et al. · 2022 · ESMO Open
71. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor
    Yuki Shinno, Akihiko Yoshida, Ken Masuda, Yuji Matsumoto, Yusuke Okuma, Tastuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yasushi Yatabe et al. · 2022 · Clinical Lung Cancer
72. Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions
    Kartik Mandal, Ganesh Kumar Barik, Manas Kumar Santra · 2025 · Molecular Cancer
73. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer
    Koji Teramoto, Tomoyuki Igarashi, Yoko Kataoka, Mitsuaki Ishida, Jun Hanaoka, Hidetoshi Sumimoto, Yataro Daigo · 2019 · Lung Cancer
74. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
    Haiying Ding, Wenxiu Xin, Yinghui Tong, Jiao Sun, Gaoqi Xu, Ziqi Ye, Yuefeng Rao · 2020 · PLoS ONE
75. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non–small-cell Lung Cancer Brain Metastases
    Tom L. Enright, Jacob S. Witt, Adam R. Burr, Poonam Yadav, Ticiana A.B. Leal, Andrew M. Baschnagel · 2020 · Clinical Lung Cancer
76. Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy
    Daijiro Harada, KENJI TAKATA, Shunta Mori, Toshiyuki Kozuki, YOSHIKA TAKECHI, Satoko Moriki, Yumi Asakura, TAKAYUKI OHNO, Naoyuki Nogami · 2019 · Anticancer Research
77. Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer
    Louise A. Koopman, Mikkel G. Terp, Gijs G. Zom, Maarten L. Janmaat, Kirstine Jacobsen, Elke Gresnigt-Van den Heuvel, Marcel Brandhorst, Ulf Forssmann, Freddy De Bree, Nora Pencheva et al. · 2019 · JCI Insight
78. Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer
    Mari Aso, Yukihiro Toi, Jun Sugisaka, Tomoiki Aiba, Sachiko Kawana, Ryohei Saito, Takahiro Ogasawara, Kyoji Tsurumi, Kana Ono, Hisashi Shimizu et al. · 2019 · The Oncologist
79. The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
    Yanhui Chen, Yating Wang, Hongli Luo, Xue Meng, Wei Zhu, Di Wang, Hui Zeng, Henghui Zhang · 2020 · Experimental Hematology and Oncology
80. Cancer neoantigens as potential targets for immunotherapy
    Weijie Ma, Brian Pham, Tianhong Li · 2021 · Clinical & Experimental Metastasis
81. Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors
    Jiebai Zhou, Yencheng Chao, Danwei Yao, Ning Ding, Jiamin Li, Lei Gao, Yong Zhang, Xiaobo Xu, Jian Zhou, Balázs Halmos et al. · 2021 · Translational Lung Cancer Research
82. Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy
    Faizan Haider Khan, Basharat Ahmad Bhat, Bashir Ahmad Sheikh, Lubna Tariq, Roshan Padmanabhan, Jay Prakash Verma, Amritesh C. Shukla, Afshin Dowlati, Ata Abbas · 2021 · Seminars in Cancer Biology
83. Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients
    Stefano Bracci, Miriam Dolciami, Claudio Trobiani, Antonella Izzo, Angelina Pernazza, Giulia d’Amati, Lucia Manganaro, Paolo Ricci · 2021 · La radiologia medica
84. The Landscape of Immunotherapy Resistance in NSCLC
    Daniele Frisone, Alex Friedlaender, Alfredo Addeo, Petros K. Tsantoulis · 2022 · Frontiers in Oncology
85. Immunotherapy approaches for malignant pleural mesothelioma
    Dean Anthony Fennell, Sean Dulloo, James Harber · 2022 · Nature Reviews Clinical Oncology
86. Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
    Saud Almawash · 2025 · Cancers
87. Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Network Meta-Analysis
    Andrew M. Frederickson, Stella Arndorfer, Ina Zhang, Maria F. Lorenzi, Ralph P. Insinga, Ashwini Arunachalam, Thomas A. Burke, George R. Simon · 2019 · Immunotherapy
88. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors
    Olivier Bylicki, Helene Barazzutti, Nicolas Paleiron, J. Margery, Jean‐Baptiste Assié, CHRISTOS CHOUAID · 2019 · BioDrugs
89. The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
    Jia Li Low, Robert John Walsh, Yvonne L.E. Ang, Gloria Hui Jia Chan, Ross Andrew Soo · 2019 · Therapeutic Advances in Medical Oncology
90. Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
    Thierry Berghmans, Valérie Durieux, Lizza E.L. Hendriks, Anne‐Marie C. Dingemans · 2020 · Frontiers in Medicine
91. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
    Joao V. Alessi, Biagio Ricciuti, Elizabeth Jimenez-Aguilar, Fangxin Hong, Zihan Wei, Mizuki Nishino, Andrew J. Plodkowski, Peter Sawan, Jia Luo, Hira A. Rizvi et al. · 2020 · Journal for ImmunoTherapy of Cancer
92. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy
    Xiaosheng Wu, Yanli Li, Xin Liu, Chunhua Chen, Susan M. Harrington, Siyu Cao, Tiancheng Xie, Tu T. Pham, Aaron Scott Mansfield, Yiyi Yan et al. · 2018 · Heliyon
93. Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
    T. Flieswasser, J. Van Loenhout, Laurie Freire Boullosa, Astrid Van Den Eynde, J. De Waele, J. V. Van Audenaerde, F. Lardon, E. Smits, P. Pauwels, J. Jacobs · 2020 · Cells
94. Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
    Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar H. Patel, Andrew C. Johns, Madison M. Grogan, Erin Marie Bertino, Kai He, Peter G. Shields et al. · 2021 · Journal of the National Comprehensive Cancer Network
95. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
    Laura Mezquita, Isabel Ruth Preeshagul, Édouard Auclin, Diana Saravia, Lizza E.L. Hendriks, Hira A. Rizvi, Wungki Park, Ernest Nadal, Patricia Martín-Romano, José Carlos Ruffinelli et al. · 2021 · European Journal of Cancer
96. Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events
    Muhammad Zain Farooq, Sheeba Ba Aqeel, Prasanth Lingamaneni, Rayli Pichardo, Aleeza Jawed, Saad Khalid, Shristi Upadhyay Banskota, Pingfu Fu, Ankit Mangla · 2022 · JAMA Network Open
97. Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
    Ren Luo, Kateryna Onyshchenko, Liqun Wang, Simone Gaedicke, Anca‐Ligia Grosu, Elke Firat, Gabriele Niedermann · 2022 · Clinical Cancer Research
98. Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
    James P. Pham, Anthony Michael Joshua, Inês Pires da Silva, Reinhard Dummer, Simone M. Goldinger · 2023 · Current Oncology Reports
99. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial
    James Chih‐Hsin Yang, Baohui Han, Emmanuel de la Mora Jimenez, Jong-Seok Lee, P. Koralewski, Nuri Karadurmuş, Shunichi Sugawara, Lorenzo Livi, Naveen S. Basappa, Xavier Quantin et al. · 2023 · Journal of Thoracic Oncology
100. Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures
     Florent Peyraud, Jean‐Philippe Guégan, Christophe Rey, Oren Lara, Ophélie Odin, Marie Del Castillo, Lucile Vanhersecke, Jean‐Michel Coindre, Emma Clot, Maxime Brunet et al. · 2025 · Cell Reports Medicine